KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment (2017 - 2025)

Historic Asset Writedowns and Impairment for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $22.8 million.

  • Amneal Pharmaceuticals' Asset Writedowns and Impairment rose 308.35% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.4 million, marking a year-over-year decrease of 274.8%. This contributed to the annual value of $96.6 million for FY2024, which is 2928.53% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Asset Writedowns and Impairment stood at $22.8 million for Q3 2025, which was up 308.35% from $23.7 million recorded in Q1 2025.
  • Amneal Pharmaceuticals' 5-year Asset Writedowns and Impairment high stood at $32.9 million for Q4 2024, and its period low was $3.6 million during Q1 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median Asset Writedowns and Impairment value was $17.3 million (recorded in 2023), while the average stood at $18.0 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Asset Writedowns and Impairment crashed by 7766.68% in 2022, and later surged by 60441.59% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $15.4 million in 2021, then soared by 44.52% to $22.2 million in 2022, then fell by 18.74% to $18.0 million in 2023, then skyrocketed by 82.54% to $32.9 million in 2024, then tumbled by 30.8% to $22.8 million in 2025.
  • Its last three reported values are $22.8 million in Q3 2025, $23.7 million for Q1 2025, and $32.9 million during Q4 2024.